Zevra Therapeutics annual return on assets (roa)
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Zevra Therapeutics Return on Assets (ROA) Growth & History (ZVRA)
Zevra Therapeutics's return on assets (roa) was 35.96% for fiscal 2025.
View full Zevra Therapeutics company overviewZevra Therapeutics annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 35.96% | +96.18 pp |
| 2024 | 2024-12-31 | −60.21% | −28.20 pp |
| 2023 | 2023-12-31 | −32.02% | −10.45 pp |
| 2022 | 2022-12-31 | −21.57% | −9.70 pp |
| 2021 | 2021-12-31 | −11.87% | +105.65 pp |
| 2020 | 2020-12-31 | −117.52% | +14.13 pp |
| 2019 | 2019-12-31 | −131.65% | +10.94 pp |
| 2018 | 2018-12-31 | −142.59% | −79.41 pp |
| 2017 | 2017-12-31 | −63.18% | −39.50 pp |
| 2016 | 2016-12-31 | −23.68% | +136.38 pp |
| 2015 | 2015-12-31 | −160.06% | — |
Zevra Therapeutics quarterly return on assets (roa)
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 20.85% | +19.53 pp |
| Q1 2026 | 2026-03-31 | 55.05% | +111.83 pp |
| Q4 2025 | 2025-12-31 | 35.96% | +96.18 pp |
| Q3 2025 | 2025-09-30 | 15.30% | +69.56 pp |
| Q2 2025 | 2025-06-30 | 1.32% | +54.78 pp |
| Q1 2025 | 2025-03-31 | −56.78% | −18.43 pp |
| Q4 2024 | 2024-12-31 | −60.21% | −28.20 pp |
| Q3 2024 | 2024-09-30 | −54.25% | −38.47 pp |
| Q2 2024 | 2024-06-30 | −53.46% | −38.96 pp |
| Q1 2024 | 2024-03-31 | −38.35% | −5.53 pp |
| Q4 2023 | 2023-12-31 | −32.02% | −10.45 pp |
| Q3 2023 | 2023-09-30 | −15.79% | +11.65 pp |
| Q2 2023 | 2023-06-30 | −14.50% | +8.59 pp |
| Q1 2023 | 2023-03-31 | −32.82% | −32.71 pp |
| Q4 2022 | 2022-12-31 | −21.57% | −9.70 pp |
| Q3 2022 | 2022-09-30 | −27.44% | −13.01 pp |
| Q2 2022 | 2022-06-30 | −23.09% | −7.26 pp |
| Q1 2022 | 2022-03-31 | −0.11% | +34.73 pp |
| Q4 2021 | 2021-12-31 | −11.87% | +105.65 pp |
| Q3 2021 | 2021-09-30 | −14.43% | +101.29 pp |
| Q2 2021 | 2021-06-30 | −15.83% | +46.29 pp |
| Q1 2021 | 2021-03-31 | −34.84% | +90.26 pp |
| Q4 2020 | 2020-12-31 | −117.52% | +14.13 pp |
| Q3 2020 | 2020-09-30 | −115.72% | +33.95 pp |
| Q2 2020 | 2020-06-30 | −62.11% | +115.73 pp |
| Q1 2020 | 2020-03-31 | −125.10% | +10.98 pp |
| Q4 2019 | 2019-12-31 | −131.65% | +10.94 pp |
| Q3 2019 | 2019-09-30 | −149.67% | +8.81 pp |
| Q2 2019 | 2019-06-30 | −177.85% | −67.69 pp |
| Q1 2019 | 2019-03-31 | −136.09% | −46.00 pp |
| Q4 2018 | 2018-12-31 | −142.59% | −79.41 pp |
| Q3 2018 | 2018-09-30 | −158.48% | −102.91 pp |
| Q2 2018 | 2018-06-30 | −110.16% | −56.97 pp |
| Q1 2018 | 2018-03-31 | −90.09% | −58.20 pp |
| Q4 2017 | 2017-12-31 | −63.18% | −39.50 pp |
| Q3 2017 | 2017-09-30 | −55.58% | −35.34 pp |
| Q2 2017 | 2017-06-30 | −53.19% | −39.04 pp |
| Q1 2017 | 2017-03-31 | −31.88% | +50.02 pp |
| Q4 2016 | 2016-12-31 | −23.68% | +136.38 pp |
| Q3 2016 | 2016-09-30 | −20.24% | — |
| Q2 2016 | 2016-06-30 | −14.15% | — |
| Q1 2016 | 2016-03-31 | −81.91% | — |
| Q4 2015 | 2015-12-31 | −160.06% | — |
Zevra Therapeutics return on assets (roa) trends
Over the last five fiscal years, Zevra Therapeutics's return on assets (roa) increased from −117.52% to 35.96%, a change of +153.48 percentage points. The latest reported quarter, Q2 2026, shows 20.85%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zevra Therapeutics source filings ↗